FindTrial
Sign In

LP-118

DRUG3 trials

Sponsors

Newave Pharmaceutical Inc, University of Chicago, Wake Forest University Health Sciences

Conditions

Acute LeukemiaAcute Lymphocytic LeukemiaAcute Myeloid LeukemiaChronic Lymphocytic LeukemiaChronic Myelomonocytic Leukemia-2Lymphoblastic LeukemiaLymphoblastic LymphomaMultiple Myeloma

Phase 1

Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
RecruitingNCT04771572
Newave Pharmaceutical IncAcute Lymphocytic Leukemia, Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia +10
Start: 2022-05-08End: 2027-12-31Target: 100Updated: 2026-05-05
A Study to Investigate LP-118, Ponatinib, Vincristine and Dexamethasone in Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LBL)
RecruitingNCT06207123
University of ChicagoAcute Leukemia, Lymphoblastic Leukemia, Lymphoblastic Lymphoma
Start: 2024-09-13End: 2026-12-01Target: 15Updated: 2026-03-18
A Study of LP-118 In Combination With Ponatinib, Dexamethasone And Blinatumomab For Adults With Newly-Diagnosed, BCR::ABL1-Positive Acute Lymphoblastic Leukemia (ALL)
Not yet recruitingNCT07614022
Wake Forest University Health SciencesPhiladelphia Positive Acute Lymphoblastic Leukemia
Start: 2026-10-01End: 2030-03-01Target: 26Updated: 2026-06-05

Related Papers

Trial in progress: A Phase I/II study to investigate the combination of LP-118, ponatinib, vincristine and dexamethasone (LPVd regimen) in relapsed/refractory T-ALL/lbl
Blood2025-11-03
Abstract 675: Targeting Bcl-2/Bcl-xl for small cell lung cancer treatment with LP-118
Cancer Research2024-03-22
LP-118, a Selective Bcl-2 Inhibitor with Tuned Bcl-Xl Activity, Causes Myeloid Differentiation and Cell Death in Acute Myeloid Leukemia (AML)
Blood2022-11-15
Targeting Apoptosis with Novel BH3 Mimetics in T-Lineage Acute Lymphoblastic Leukemia
Blood2022-11-15
Characterization of LP-118, a Novel Small Molecule Inhibitor of Bcl-2 and Bcl-Xl in Chronic Lymphocytic Leukemia Resistant to Venetoclax
Blood2021-11-059 citations